Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
Early data whet appetites ahead of the big event for one of the few remaining antiviral hopes in Covid-19.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.